Journal of Clinical Endocrinology & Metabolism, Vol 71, 688-695, Copyright © 1990 by Endocrine Society

ARTICLES

Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation

AC Hokken-Koelega, WH Hackeng, T Stijnen, JM Wit, SM de Muinck Keizer-Schrama and SL Drop
Department of Pediatrics, Sophia Children's Hospital/Erasmus University, Rotterdam, The Netherlands.

We studied 24-h plasma GH profiles, maximal GH responses to arginine provocation and insulin-like growth factor-I (IGF-I) and IGF-II levels in plasma in 22 euthyroid prepubertal children (mean age, 9.5 yr) with chronic renal insufficiency (glomerular filtration rate, less than 20 mL/min.1.73 m2) and severe growth retardation [mean (+/- SD) height SD score (SDS), -2.8 (1.1)]. The 24-h GH profiles were analyzed using the Pulsar program. Girls had significantly higher 24-h GH secretion than boys (P less than 0.004). Children with end-stage nephrotic syndrome had higher baseline GH levels and total area under the curve (AUCo) than patients with dysplastic kidneys (P less than 0.05), while the area under the curve above baseline (AUCb) was similar in all types of renal diseases. The type of treatment (conservative, peritoneal, hemodialysis) did not significantly influence the 24-h GH secretion. No correlation was found between 24-h GH profiles and age, height SDS for chronological age, height velocity SDS for bone age, and weight for height. Fourteen children showed a normal 24-h GH profile, defined as a GH profile with well defined, regular GH peaks returning to baseline GH levels and a distinct day and night pattern (AUCb, 90-300 micrograms/L.24 h). Four children had low profiles, with GH peaks below 10 micrograms/L, returning to baseline GH levels and occurring almost exclusively during the night (AUCb, less than 90 micrograms/L.24 h). The remaining four children had elevated 24-h GH profiles, with GH peaks on top of elevated baseline GH levels of more than 3 micrograms/L (AUCb, 35-205 micrograms/L.24 h; AUCo greater than 300 micrograms/L.24 h). In all patients 24-h urinary GH and beta 2-globulin excretion was 100-1000 times higher than that in controls. The urinary GH excretion correlated significantly with all characteristics of the 24-h GH profiles (r = 0.57-0.59; P less than 0.05). The maximal GH response during the arginine tolerance test was normal in 66% of the children. The mean (+/- SD) SDS for bone age for the IGF-I plasma levels was +1.1 (1.9), and that for IGF-II was +3.6 (3.4). IGF-I levels correlated significantly with the AUCb, maximum GH, and GH peak characteristics of the 24-h GH profiles (r = 0.05-0.73; P less than 0.02-0.001). IGF-II levels did not show any correlation with the characteristics of the endogenous GH secretion.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				M. A. J. de Ridder, T. Stijnen, and A. C. S. Hokken-Koelega Prediction Model for Adult Height of Small for Gestational Age Children at the Start of Growth Hormone Treatment J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 477 - 483. [Abstract] [Full Text] [PDF]

				D. A. M. Festen, A. van Toorenenbergen, H. J. Duivenvoorden, and A. C. S. Hokken-Koelega Adiponectin Levels in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Therapy J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1549 - 1554. [Abstract] [Full Text] [PDF]

				M. van Dijk, E. M. N. Bannink, Y. K. van Pareren, P. G. H. Mulder, and A. C. S. Hokken-Koelega Risk Factors for Diabetes Mellitus Type 2 and Metabolic Syndrome Are Comparable for Previously Growth Hormone-Treated Young Adults Born Small for Gestational Age (SGA) and Untreated Short SGA Controls J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 160 - 165. [Abstract] [Full Text] [PDF]

				M. van Dijk, P. Mulder, M. Houdijk, J. Mulder, K. Noordam, R. J. Odink, C. Rongen-Westerlaken, P. Voorhoeve, J. Waelkens, J. Stokvis-Brantsma, et al. High Serum Levels of Growth Hormone (GH) and Insulin-Like Growth Factor-I (IGF-I) during High-Dose GH Treatment in Short Children Born Small for Gestational Age J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1390 - 1396. [Abstract] [Full Text] [PDF]

				M. J. E. Walenkamp, M. Karperien, A. M. Pereira, Y. Hilhorst-Hofstee, J. van Doorn, J. W. Chen, S. Mohan, A. Denley, B. Forbes, H. A. van Duyvenvoorde, et al. Homozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2855 - 2864. [Abstract] [Full Text] [PDF]

				Y. Van Pareren, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Adult Height after Long-Term, Continuous Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age: Results of a Randomized, Double-Blind, Dose-Response GH Trial J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3584 - 3590. [Abstract] [Full Text] [PDF]

				J. van Doorn, C. M. Hoogerbrugge, J. G. Koster, R. J. Bloemen, K. Hoekman, A. H. Mudde, and S. C. van Buul-Offers Antibodies Directed against the E Region of Pro-Insulin-like Growth Factor-II Used to Evaluate Non-Islet Cell Tumor-induced Hypoglycemia Clin. Chem., October 1, 2002; 48(10): 1739 - 1750. [Abstract] [Full Text] [PDF]

				F. de Groof, K. F. M. Joosten, J. A. M. J. L. Janssen, E. D. de Kleijn, J. A. Hazelzet, W. C. J. Hop, P. Uitterlinden, J. van Doorn, and A. C. S. Hokken-Koelega Acute Stress Response in Children with Meningococcal Sepsis: Important Differences in the Growth Hormone/Insulin-Like Growth Factor I Axis between Nonsurvivors and Survivors J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3118 - 3124. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, and A. D. Rogol Gender and Sexual Maturation-Dependent Contrasts in the Neuroregulation of Growth Hormone Secretion in Prepubertal and Late Adolescent Males and Females--A General Clinical Research Center-Based Study J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2385 - 2394. [Abstract] [Full Text]

				T. Sas, W. de Waal, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3064 - 3070. [Abstract] [Full Text]

				T. C J Sas, S M P F d. M. Keizer-Schrama, T. Stijnen, A van Teunenbroek, A C S Hokken-Koelega, J J J Waelkens, G G Massa, T. Vulsma, W J Gerver, H M Reeser, et al. Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections Arch. Dis. Child., January 1, 1999; 80(1): 36 - 41. [Abstract] [Full Text]

				A M Boot, J Bouquet, E P Krenning, and S M P F de Muinck Keizer-Schrama Bone mineral density and nutritional status in children with chronic inflammatory bowel disease Gut, February 1, 1998; 42(2): 188 - 194. [Abstract] [Full Text] [PDF]

				A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2423 - 2428. [Abstract] [Full Text] [PDF]